OncoDxRx Unveils Breakthrough Technology for Those Cancer Patients with Negative Biomarker Testing
A new "build-for-purpose” test was unveiled by OncoDxRx. The proprietary technology aims at broadening the coverage of tailored personalized diagnostics and therapeutics to those cancer patients currently excluded from precision medicine.
- (1888PressRelease) December 24, 2022 - Faced with the assertion of advanced genomic profiling technologies in the fight against cancer and the consensus of precision medicine (targeted therapy and immunotherapy), the genetic care of “all” (not limited to 20-30% eligible population) cancer patients should be a decisive goal for next-generation cancer management.
PGA technology (Patient-derived Gene expression-informed Anti-cancer drug efficacy) aims to integrate the new tool into the existing precision medicine testing workup. This innovation will be articulated around three functions “blood draw”, “personalized report” and “treatment with the most effective drug(s)”.
The industry already has next-generation sequencing (NGS) and digital PCR testing capabilities contributing to precision medicine. However, both platforms can only qualify 20-30% cancer patients for targeted therapies, leaving 70-80% patients out of precision medicine. OncoDxRx’s PGA technology, on the other hand, targets this 70-80% population whose biomarker testing are negative, hence completing the puzzle and benefiting the entire cancer population.
“We are obviously the only one interested in this patient population. There are many companies that display their ambitions toward targeted therapy and immunotherapy, even though both apply only to a very limited numbers of patients.” OncoDxRx said.
OncoDxRx’s patent-pending, transformative PGA can provide comprehensive anti-cancer drug efficacy data within 5 days and improve the clinical-benefit rate for cancer patients. The firm added that PGA’s unprecedented potential of selecting optimal treatment regimen among hundreds of anti-cancer drugs for individual patients based on patients’ own gene expression profiles will impact the cancer genetic care profoundly.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam